Quantitative proteomic analysis reveals maturation as a mechanism underlying glucocorticoid resistance in B lineage ALL and re-sensitization by JNK inhibition.
Authors
Nicholson, LEvans, Caroline A
Matheson, E
Minto, L
Keilty, C
Sanichar, M
Case, M
Schwab, C
Williamson, D
Rainer, J
Harrison, C
Kofler, R
Hall, A
Redfern, C
Whetton, Anthony D
Irving J
Affiliation
Newcastle Cancer Centre at the Northern Institute for Cancer Research, Newcastle University, Newcastle upon Tyne, UKIssue Date
2015-08-27
Metadata
Show full item recordAbstract
Glucocorticoid (GC) resistance is a continuing clinical problem in childhood acute lymphoblastic leukaemia (ALL) but the underlying mechanisms remain unclear. A proteomic approach was used to compare profiles of the B-lineage ALL GC-sensitive cell line, PreB 697, and its GC-resistant sub-line, R3F9, pre- and post-dexamethasone exposure. PAX5, a transcription factor critical to B-cell development was differentially regulated in the PreB 697 compared to the R3F9 cell line in response to GC. PAX5 basal protein expression was less in R3F9 compared to its GC-sensitive parent and confirmed to be lower in other GC-resistant sub-lines of Pre B 697 and was associated with a decreased expression of the PAX5 transcriptional target, CD19. Gene set enrichment analysis showed that increasing GC-resistance was associated with differentiation from preB-II to an immature B-lymphocyte stage. GC-resistant sub-lines were shown to have higher levels of phosphorylated JNK compared to the parent line and JNK inhibition caused re-sensitization to GC. Exploiting this maturation may be key to overcoming GC resistance and targeting signalling pathways linked to the maturation state, such as JNK, may be a novel approach.Citation
Quantitative proteomic analysis reveals maturation as a mechanism underlying glucocorticoid resistance in B lineage ALL and re-sensitization by JNK inhibition. 2015: Br J HaematolJournal
British Journal of HaematologyDOI
10.1111/bjh.13647PubMed ID
26310606Type
ArticleLanguage
enISSN
1365-2141ae974a485f413a2113503eed53cd6c53
10.1111/bjh.13647
Scopus Count
Collections
Related articles
- Piperlongumine inhibits the proliferation and survival of B-cell acute lymphoblastic leukemia cell lines irrespective of glucocorticoid resistance.
- Authors: Han SS, Han S, Kamberos NL
- Issue date: 2014 Sep 26
- Evaluation of PAX5 gene in the early stages of leukemic B cells in the childhood B cell acute lymphoblastic leukemia.
- Authors: Firtina S, Sayitoglu M, Hatirnaz O, Erbilgin Y, Oztunc C, Cinar S, Yildiz I, Celkan T, Anak S, Unuvar A, Devecioglu O, Timur C, Aydogan G, Akcay A, Atay D, Turkkan E, Karaman S, Orhaner B, Sarper N, Deniz G, Ozbek U
- Issue date: 2012 Jan
- Binimetinib, a novel MEK1/2 inhibitor, exerts anti-leukemic effects under inactive status of PI3Kinase/Akt pathway.
- Authors: Sakakibara K, Tsujioka T, Kida JI, Kurozumi N, Nakahara T, Suemori SI, Kitanaka A, Arao Y, Tohyama K
- Issue date: 2019 Aug
- Cucurbitacin-I (JSI-124) activates the JNK/c-Jun signaling pathway independent of apoptosis and cell cycle arrest in B leukemic cells.
- Authors: Ishdorj G, Johnston JB, Gibson SB
- Issue date: 2011 Jun 24
- Anisomycin induces apoptosis of glucocorticoid resistant acute lymphoblastic leukemia CEM-C1 cells via activation of mitogen-activated protein kinases p38 and JNK.
- Authors: Liu Y, Ge J, Li Q, Gu L, Guo X, Ma ZG, Zhu YP
- Issue date: 2013